Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients.
Although deferoxamine mesylate (DFO) is effective in removing aluminum (Al) in hemodialysis patients, treatment with this drug is associated with a number of adverse effects. In order to limit the exposure of patients to DFO-Al complexes, the efficacy of colloidin-coated microencapsulated charcoal cartridges added in series to conventional dialyzers was investigated. The clearances of Al by the sorbent system were initially 116 +/- 4.7 mL/min, but decreased to 42.5 +/- 6.6 mL/min after 120 minutes of treatment. Thereafter, the Al clearances remained constant. In contrast, the Al clearances of the dialyzer were 29.5 +/- 1.8 mL/min initially and did not change during the treatment period. Both the percent and absolute decrease in Al levels after four hours of dialysis were greater with the dialyzers plus carbon cartridges than with the dialyzers alone. This resulted in an increase in the minimum net Al removal from 1,862 +/- 174 micrograms/treatment to 3,007 +/- 43 micrograms/treatment (P less than 0.05). Treatment with sorbent hemoperfusion should be considered in selected hemodialysis patients being treated with DFO for Al overload.
Delmez
J
J
Chromalloy American Kidney Center, Washington University School of Medicine, St Louis, MO 63110.
Weerts
C
C
Lewis-Finch
J
J
Windus
D
D
Slatopolsky
E
E
D000535:Aluminum / Q000097:blood*; D002606:Charcoal; D003676:Deferoxamine / Q000627:therapeutic use*; D006464:Hemoperfusion; D006801:Humans; D007688:Kidneys, Artificial; D006435:Renal Dialysis
D002606:Charcoal; D000535:Aluminum; D003676:Deferoxamine